Ensuring High Purity Cell Therapy Products: A Focus On Accurately Characterizing Cell Aggregates, Residual Dynabeads, And Other Product Impurities
Cell therapies offer unprecedented therapeutic potential for the treatment and even cure of a wide range of diseases. However, several key challenges remain in manufacturing safe and compliant cell therapy products. As with all biologics, it is crucial to ensure formulation, stability, and purity in cell therapy products to reduce immunogenic risks, ensure long-lasting products, and enable uninterrupted administration.
In this webinar, our Chief Scientific Officer and co-founder, Dr. Bernardo Cordovez, explains how Aura+ enables complete product purity characterization by imaging, counting, and identifying cells and particle impurities in cell products. This webinar specifically focuses on cell counting, viability, aggregate characterization, and measuring residual Dynabeads™️.
About the speaker:
Dr. Bernardo Cordovez is Co-Founder and Chief Scientific officer of Halo Labs, leading the company’s research and development. Prior to starting Halo Labs, Bernardo was a Postdoctoral Associate at Cornell University, where he also obtained his M.S. and Ph.D. His wide range of technical experience includes particle analysis, detection and manipulation, drug delivery devices, microfluidics, photonics and bioenergy production.